Clinical Trials
52 trialsFLAURA
AstraZeneca
RELAY
Eli Lilly and Company
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)
Allist Pharmaceuticals, Inc.
SOLAR
Astellas Pharma Inc
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
Beta Pharma, Inc.
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
Canadian Cancer Trials Group
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
Sindas
Sichuan Provincial People's Hospital
IMPRESS
AstraZeneca
ADJUVANT
Guangdong Association of Clinical Trials
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
FL-ALTER
Sun Yat-sen University
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
RCTACSCNSCLC
Shenzhen People's Hospital
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
Sun Yat-sen University
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer
ISCAN
Guangdong Association of Clinical Trials
Iressa Follow-up Trial
AstraZeneca
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Shanghai Pulmonary Hospital, Shanghai, China
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Sun Yat-sen University
Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
Tang-Du Hospital
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
National Cancer Institute (NCI)
ICOGEN
Betta Pharmaceuticals Co., Ltd.
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
IPASS
AstraZeneca
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
IMAC/Herbst
AstraZeneca
Iressa Expanded Access Program (EAP)
AstraZeneca
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
ISTANA
AstraZeneca
RANGE
Fondazione Humanitas per la Ricerca
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
AstraZeneca
Iressa Versus Docetaxel (Taxotere)
AstraZeneca
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
Zhejiang Cancer Hospital
Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Samsung Medical Center
Open-Label Extension of Other SZ1839 (Iressa) Trials
AstraZeneca
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Telik